Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Apr. 14, 2022 | Jun. 30, 2021 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001653821 | ||
Entity Registrant Name | CEN BIOTECH INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2021 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 000-55557 | ||
Entity Incorporation, State or Country Code | A6 | ||
Entity Address, Address Line One | 300-3295 Quality Way | ||
Entity Address, City or Town | Windsor | ||
Entity Address, State or Province | ON | ||
Entity Address, Postal Zip Code | N8T 3R9 | ||
City Area Code | 519 | ||
Local Phone Number | 419-4958 | ||
Title of 12(g) Security | Common Stock, No Par Value per share | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 13,029,000 | ||
Entity Common Stock, Shares Outstanding | 56,407,410 | ||
Auditor Name | Mazars USA LLP | ||
Auditor Location | New York, New York | ||
Auditor Firm ID | 339 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash and cash equivalents | $ 193,198 | $ 1,908 |
Accounts receivable | 193,094 | 0 |
Prepaid expenses and other assets | 50,530 | 0 |
Income taxes refundable | 35,399 | 0 |
Loan receivable from Emergence Global Enterprises Inc. - related party | 0 | 17,901 |
Total current assets | 472,221 | 19,809 |
Other assets | ||
Operating lease right-of-use assets | 138,103 | 0 |
Other receivable | 0 | 113,999 |
Note receivable - CEN Biotech Ukraine LLC - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine LLC - related party | 1,299,328 | 1,179,328 |
Property and equipment, net | 97,403 | 0 |
Deferred income taxes | (2,720) | 0 |
Intangible assets, net | (5,072,031) | (4,956,147) |
Goodwill | 1,314,134 | 0 |
Total assets | 8,440,799 | 6,314,142 |
Current liabilities | ||
Accounts payable | 440,332 | 190,716 |
Accounts payable – related parties | 101,422 | 8,347 |
Loans payable | 1,688,793 | 527,379 |
Loans payable – related parties | 2,701,641 | 1,363,354 |
Convertible notes payable, net of unamortized discount | 643,330 | 6,652,448 |
Convertible notes payable, net of unamortized discount - related parties | 162,639 | 2,558,681 |
Accrued interest | 1,361,689 | 1,125,034 |
Accrued interest – related parties | 1,873,455 | 1,615,880 |
Operating lease liabilities | 103,908 | 22,895 |
Governmental assistance payable | 145,333 | 0 |
Accrued expenses | 638,073 | 641,023 |
Total current liabilities | 9,860,615 | 14,705,757 |
Operating lease liabilities, less current portion | 206,763 | 142,102 |
CEBA loan payable | 31,552 | 0 |
Patent acquisition liability | 0 | 1,380,000 |
Convertible notes, less current portion | 0 | 78,000 |
Total liabilities | 10,098,930 | 16,305,859 |
Commitments and contingencies (Notes 4, 11, 12, 18, 19, 24, and 25) | ||
Shareholders’ deficit | ||
Common stock; unlimited authorized shares; 55,957,743 and 27,557,363 issued and outstanding as of December 31, 2021 and 2020, respectively. No par value. | 0 | 0 |
Additional paid-in capital | 44,339,973 | 17,068,810 |
Accumulated deficit | (45,964,183) | (27,060,527) |
Accumulated other comprehensive loss | (33,921) | 0 |
Total shareholders’ deficit | (1,658,131) | (9,991,717) |
Total liabilities and shareholders’ deficit | $ 8,440,799 | $ 6,314,142 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, shares issued (in shares) | 55,957,743 | 27,557,363 |
Common stock, shares outstanding (in shares) | 55,957,743 | 27,557,363 |
Common stock, authorized | Unlimited | Unlimited |
Consolidated Statements of Oper
Consolidated Statements of Operations and Other Comprehensive (Loss) Income - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | $ 626,867 | $ 0 |
Operating expenses | ||
Consulting fees | 1,243,294 | 298,077 |
Consulting fees – related parties | 188,718 | 124,800 |
General and administrative | 16,900,582 | 1,784,766 |
Settlement of lighting patent purchase | 1,331,814 | 0 |
Loss on operating lease right-of-use asset - lease abandonment | 0 | 146,795 |
Loss on lease termination | 0 | 53,692 |
Loss on disposal of property and equipment | 0 | 135,600 |
Total operating expenses | 19,664,408 | 2,543,730 |
Loss from operations | (19,037,541) | (2,543,730) |
Other income (expense) | ||
Gain on derecognition of debt and accrued interest | 0 | 21,179,043 |
Interest expense | (428,249) | (3,233,421) |
Interest expense – related parties | (418,500) | (443,437) |
Interest income | 504 | 6,400 |
Change in fair value of patent acquisition liability | 971,500 | (660,000) |
Foreign exchange loss | (27,726) | (55,210) |
Other income, net | 97,529 | 16,793,375 |
(Loss) income before income taxes | (18,940,012) | 14,249,645 |
Income tax benefit | (36,356) | 0 |
Net (loss) income | (18,903,656) | 14,249,645 |
Other comprehensive loss - Foreign currency translation | (33,921) | 0 |
Comprehensive (loss) income | $ (18,937,577) | $ 14,249,645 |
Net (Loss) Income Per Share: | ||
Basic (in dollars per share) | $ (0.45) | $ 0.52 |
Diluted (in dollars per share) | $ (0.45) | $ 0.45 |
Weighted Average Number of Shares Outstanding | ||
Basic (in shares) | 42,417,416 | 27,264,072 |
Diluted (in shares) | 42,417,416 | 32,732,510 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Deficit - USD ($) | Conversion of Convertible Notes into Common Stock [Member]Common Stock [Member] | Conversion of Convertible Notes into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Convertible Notes into Common Stock [Member]Retained Earnings [Member] | Conversion of Convertible Notes into Common Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Convertible Notes into Common Stock [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Common Stock [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Additional Paid-in Capital [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Retained Earnings [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]AOCI Attributable to Parent [Member] | Conversion of Related Party Convertible Notes into Common stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balances (in shares) at Dec. 31, 2019 | 26,953,363 | ||||||||||||||
Balances at Dec. 31, 2019 | $ 0 | $ 15,775,010 | $ (41,310,172) | $ 0 | $ (25,535,162) | ||||||||||
Stock-based compensation (in shares) | 0 | ||||||||||||||
Stock-based compensation | $ 0 | 746,300 | 0 | 0 | 746,300 | ||||||||||
Issuance of common stock - interest shares (in shares) | 180,000 | ||||||||||||||
Issuance of common stock - interest shares | $ 0 | 159,300 | 0 | 0 | 159,300 | ||||||||||
Issuance of common stock - consulting (in shares) | 387,500 | ||||||||||||||
Issuance of common stock - consulting | $ 0 | 279,000 | 0 | 0 | 279,000 | ||||||||||
Issuance of common stock - settlement of accrued liability (in shares) | 0 | ||||||||||||||
Issuance of common stock - settlement of accrued liability | $ 0 | 58,500 | 0 | 0 | 58,500 | ||||||||||
Issuance of common stock – lease termination settlement (in shares) | 36,500 | ||||||||||||||
Issuance of common stock – lease termination settlement | $ 0 | 50,700 | 0 | 0 | 50,700 | ||||||||||
Net (loss) income | $ 0 | 0 | 14,249,645 | 14,249,645 | |||||||||||
Net loss | 14,249,645 | ||||||||||||||
Balances (in shares) at Dec. 31, 2020 | 27,557,363 | ||||||||||||||
Balances at Dec. 31, 2020 | $ 0 | 17,068,810 | (27,060,527) | 0 | (9,991,717) | ||||||||||
Stock-based compensation (in shares) | 13,909,291 | ||||||||||||||
Stock-based compensation | $ 0 | 15,390,822 | 0 | 0 | 15,390,822 | ||||||||||
Issuance of common stock - interest shares (in shares) | 158,000 | ||||||||||||||
Issuance of common stock - interest shares | $ 0 | 135,166 | 0 | 0 | 135,166 | ||||||||||
Issuance of common stock - consulting (in shares) | 1,150,000 | ||||||||||||||
Issuance of common stock - consulting | $ 0 | 1,172,000 | 0 | 0 | 1,172,000 | ||||||||||
Issuance of common stock - settlement of accrued liability (in shares) | 8,369 | ||||||||||||||
Issuance of common stock - settlement of accrued liability | $ 0 | 13,390 | 0 | 0 | 13,390 | ||||||||||
Net (loss) income | (18,903,656) | ||||||||||||||
Issuance of common stock - settlement of patent acquisition (in shares) | 5,000,000 | ||||||||||||||
Issuance of common stock - settlement of patent acquisition | $ 0 | 2,042,500 | 0 | 0 | 2,042,500 | ||||||||||
Issuance of common stock - acquisition of Clear Com Media, Inc. (in shares) | 4,000,000 | ||||||||||||||
Issuance of common stock - acquisition of Clear Com Media, Inc. | $ 0 | 2,120,000 | 0 | 0 | 2,120,000 | ||||||||||
Beneficial conversion feature on convertible notes issued | $ 0 | 198,239 | 0 | 0 | 198,239 | ||||||||||
Issuance of common stock – upon conversion of convertible notes (in shares) | 3,488,883 | 591,480 | |||||||||||||
Issuance of common stock – upon conversion of convertible notes | $ 0 | $ 5,173,785 | $ 0 | $ 0 | $ 5,173,785 | $ 0 | $ 946,368 | $ 0 | $ 0 | $ 946,368 | |||||
Issuance of common stock – settlement of accrued interest (in shares) | 94,357 | 94,357 | |||||||||||||
Issuance of common stock – settlement of accrued interest | $ 0 | 78,893 | 0 | 0 | 78,893 | ||||||||||
Net loss | $ 0 | 0 | (18,903,656) | (33,921) | (18,937,577) | ||||||||||
Balances (in shares) at Dec. 31, 2021 | 55,957,743 | ||||||||||||||
Balances at Dec. 31, 2021 | $ 0 | $ 44,339,973 | $ (45,964,183) | $ (33,921) | $ (1,658,131) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities | ||
Net (loss) income | $ (18,903,656) | $ 14,249,645 |
Adjustments to reconcile net (loss) income to net cash used in operating activities | ||
Depreciation | 22,164 | 10,724 |
Amortization | 439,543 | 424,812 |
Amortization of debt discount | 112,940 | 0 |
Deferred income tax benefit | (2,735) | 0 |
Lease expense | 41,950 | 15,870 |
Loss on disposal of property and equipment | 0 | 135,600 |
Loss on operating lease right-of-use asset - lease abandonment | 0 | 146,795 |
Loss on operating lease right-of-use asset - lease termination settlement | 0 | 2,992 |
Stock-based compensation - employees | 15,390,822 | 746,300 |
Stock-based compensation - non-employees | 1,172,000 | 279,000 |
Stock-based settlement of accrued interest | 54,657 | 0 |
Settlement of lighting patent purchase | 1,331,814 | 0 |
Shares issued related to lease termination settlement | 0 | 50,700 |
Shares issued for interest | 135,166 | 159,300 |
Non-cash services expense | 0 | 19,000 |
Change in fair value of patent acquisition liability | (971,500) | 660,000 |
Gain on derecognition of debt | 0 | (21,179,043) |
Foreign exchange loss | 27,726 | 55,210 |
Changes in operating assets and liabilities which provided (used) cash, net of amounts acquired in 2021 business combination | ||
Accounts receivable | 14,174 | 0 |
Prepaid expenses and other assets | (16,956) | 0 |
Income taxes | 25,670 | 0 |
Other receivable | 89,370 | 310,111 |
Accounts payable | 143,934 | (2,507) |
Accounts payable – related parties | 38,828 | 8,347 |
Accrued interest – related and non-related parties | 514,155 | 3,441,595 |
Operating lease payments | (28,155) | 0 |
Governmental assistance payable | 146,144 | 0 |
Accrued expenses | (113,559) | 124,800 |
Net cash used in operating activities | (335,504) | (340,749) |
Cash flows from investing activities | ||
Cash acquired upon acquisition of Clear Com Media, Inc. | 259,470 | 0 |
Loan to Emergence Global Enterprises Inc. | 0 | (17,901) |
Advances to CEN Biotech Ukraine LLC | (120,000) | (114,000) |
Capitalized software development | (106,320) | 0 |
Purchases of equipment | (23,213) | 0 |
Proceeds from sale of equipment | 0 | 1,801 |
Net cash provided by (used in) investing activities | 9,937 | (130,100) |
Cash flows from financing activities | ||
Repayment of loans payable - related parties | (50,000) | 0 |
Issuance of convertible notes | 522,830 | 499,000 |
Repayment of convertible notes | 0 | (30,000) |
Issuance of convertible notes - related parties | 48,000 | 0 |
Net cash provided by financing activities | 520,830 | 469,000 |
Effect of exchange rate changes on cash | (3,973) | 0 |
Net increase (decrease) in cash and cash equivalents | 191,290 | (1,849) |
Cash and cash equivalents, beginning of year | 1,908 | 3,757 |
Cash and cash equivalents, end of year | 193,198 | 1,908 |
Supplemental cash flows disclosures | ||
Cash paid for interest | 25,818 | 75,963 |
Non-cash transactions - investing and financing activities | ||
Issuance of common stock - settlement of interest | 78,893 | 0 |
Issuance of common stock - settlement of accrued liability | 13,390 | 58,500 |
Issuance of common stock - settlement of patent acquisition | 2,042,500 | 0 |
Settlement of receivable from Emergence Global Enterprises Inc. | 17,901 | 0 |
Waiver of conversion rights on convertible loans payable | 1,462,484 | 0 |
Waiver of conversion rights on convertible loans payable - related parties | 1,388,122 | 0 |
Transfer of convertible notes – related parties to convertible notes | 102,395 | 0 |
Debt assumed by seller as part of lighting patent purchase | 302,187 | 0 |
Issuance of note payable for services | 0 | 19,000 |
Clear Com Media, Inc [Member] | ||
Acquisition of Clear Com Media, Inc.: | ||
Fair value of assets acquired | 2,604,669 | 0 |
Issuance of common stock - acquisition of Clear Com Media, Inc. | 2,120,000 | 0 |
Liabilities assumed | 484,669 | 0 |
Convertible Debt [Member] | ||
Non-cash transactions - investing and financing activities | ||
Debt Instrument, Convertible, Beneficial Conversion Feature | 198,239 | 0 |
Conversion of Convertible Notes into Common Stock [Member] | ||
Non-cash transactions - investing and financing activities | ||
Debt Conversion, Converted Instrument, Amount | 5,173,785 | 0 |
Conversion of Related Party Convertible Notes into Common stock [Member] | ||
Non-cash transactions - investing and financing activities | ||
Debt Conversion, Converted Instrument, Amount | $ 946,368 | $ 0 |
Note 1 - Nature of Business
Note 1 - Nature of Business | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | NOTE 1 NATURE OF BUSINESS CEN Biotech, Inc. (“CEN”) was incorporated in Canada on August 4, 2013 February 29, 2016, The consolidated financial statements also include the accounts of Eastern Starr Biotech, Inc. (“Eastern Starr”), a Georgia corporation that was acquired on August 22, 2017 July 9, 2021, CEN is focused on the manufacturing, production and development of products within the cannabis industry, including the LED lighting technology and hemp products. CEN intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products. CCM focuses on providing digital marketing and web design related services. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation CEN’s consolidated financial statements include the accounts of CEN, CCM, and Eastern Starr (collectively, the “Company”). CCM is a Windsor, Ontario based digital marketing, and e-commerce company. CCM’s purpose is to develop, market and sell various digital products. Additionally, CCM will provide in-house IT support functions for CEN’s activities. Eastern Starr’s purpose is to facilitate future growth opportunities in the LED lighting sector. All material intercompany transactions are eliminated in consolidation. Basis of Accounting The Company’s consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar. Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets and goodwill), and the reported amounts of revenues and expenses during the reporting period, including stock-based compensation. Accordingly, actual results may Revenue from Contracts with Customers The Company has agreements with third no not not not The Company derived approximately 99% of its revenue from one customer during the year ended December 31, 2021. December 31, 2021 Cash and Cash Equivalents For purposes of the consolidated balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three Accounts Receivable Accounts receivable are customer obligations due under normal trade terms generally requiring payment within 30 60 no not Property and Equipment Property and equipment are recorded at cost. Major improvements and renewals are capitalized while ordinary maintenance and repairs are expensed. Management reviews these assets for impairment whenever events or changes in circumstances indicate the related carrying amount may not See Note 6 2020 Intangible Assets Trade Names and Customer Relationships may not Product Technology and Capitalized Software Development Costs 985 20 25, Costs of Software to Be Sold, Leased or Marketed not December 31, 2021. Lighting Patent may not may not Goodwill Goodwill arising from business combinations represents the excess of purchase consideration exchanged by the Company over the estimated fair value of the net assets of acquired businesses. The Company evaluates goodwill for impairment on an annual basis. In completing this evaluation, the Company considers the profitability of Clear Com Media, Inc. and compares its best estimate of future cash flows with the net carrying value of goodwill. Research and Development Expenditures The Company expenses all research and development expenses when incurred. There were no 2021 2020. Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities. Foreign Currency Foreign denominated monetary assets and liabilities of the Company are translated at the rate of exchange prevailing at the consolidated balance sheet date. Other assets and liabilities denominated in foreign currencies are translated at the exchange rates prevailing when the assets were acquired or the liabilities incurred. Sales and expenses are translated at the average exchange rate over the reporting period. Transaction gains or losses are included in the determination of net (loss) income. The functional currency of CCM is the Canadian dollar. The accounts of CCM were translated to United States dollars equivalents at exchange rates as follows: balance sheet assets and liabilities were converted at period-end rates, equity at historical rates, and income statement accounts at average rates for the period. The resulting translation gain or loss is reflected in other comprehensive loss and accumulated other comprehensive loss in the consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ deficit, respectively. Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, Compensation Stock Compensation 718 718 (Loss) Income per Share Net (loss) income per common share is computed pursuant to Accounting Standards Codification (ASC) 260 10 45. 2021, not 21. Leases The Company accounts for leases pursuant to ASC Topic 842, Leases not 2020, 20 18. Reclassification Certain amounts as reported in the 2020 2021 |
Note 3 - New Accounting Standar
Note 3 - New Accounting Standards | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Accounting Standards Update and Change in Accounting Principle [Text Block] | NOTE 3 NEW ACCOUNTING STANDARDS Recently Adopted Accounting Pronouncements No no 2021. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. January 1, 2022. |
Note 4 - Going Concern Uncertai
Note 4 - Going Concern Uncertainty / Management Plans | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 4 GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $45,964,183 at December 31, 2021 no not July 9, 2021 not 9, 10, 11, 12. 19 no not The Company’s cash position may not |
Note 5 - Acquisition of Clear C
Note 5 - Acquisition of Clear Com Media, Inc. | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | NOTE 5 ACQUISTION OF CLEAR COM MEDIA, INC. As described in Note 1, July 9, 2021. The merger was accounted for as a business combination using the acquisition method of accounting under the provisions of Accounting Standards Codification (ASC) 805, 805 805 See Note 23 The aggregate consideration for the acquisition of CCM was 4,000,000 shares of CEN common stock, which were issued pursuant to an exemption from registration under Section 4 2 1933, not July 9, 2021. September 30, 2021, December 31, 2021, September 30, 2021 Cash $ 259,470 Accounts receivable 210,536 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 456,855 Current financial liabilities (344,591 ) Other long-term liabilities (140,078 ) Total identifiable net assets 784,643 Goodwill 1,335,357 Net assets acquired $ 2,120,000 Identified intangible assets acquired includes trade names, customer relationships, and product technology whose fair value of $456,855 is based on an appraisal report utilizing a combination of market, income, and multi-period excess earnings methods. These trade names and customer relationships are being amortized over useful-lives ranging of 3 and 7 years, respectively, and the product technology is not not Amounts recognized as goodwill are expected to be fully deductible for Canadian income tax purposes. All goodwill has been included within the Digital segment. Costs related to the acquisition, which include legal, accounting, and valuation fees, in the amount of approximately $80,000 have been charged directly to operations and are included in general and administrative expenses in the 2021 Supplemental proforma financial information The unaudited financial information in the table below summarizes the combined results of operations of CEN and CCM on a pro forma basis, as though the companies had been combined as of the January 1, 2020. not January 1, 2020. 4,000,000 January 1, 2020 The pro forma financial information for the year ended December 31, 2021 2021, July 9, 2021, January 1, 2021 July 8, 2021. December 31, 2020 2020 2020. The following table summarizes the pro forma financial information (unaudited): Years Ended December 31, 2021 December 31, 2020 Revenue $ 1,305,985 $ 1,242,676 Operating expenses 20,437,863 3,720,279 Loss from operations (19,131,878 ) (2,477,603 ) Other income, net 57,949 16,950,653 (Loss) income before income taxes (19,073,929 ) 14,473,050 Income tax expense (61,032 ) 32,892 Net (loss) income $ (19,012,897 ) $ 14,440,158 Net (Loss) Income Per Share Basic $ (0.43 ) $ 0.46 Diluted $ (0.43 ) $ 0.39 Weighted Average Number of Shares Outstanding Basic 44,488,649 31,264,072 Diluted 44,488,649 36,732,510 |
Note 6 - Property, Plant and Im
Note 6 - Property, Plant and Improvements, Net | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 6 PROPERTY, PLANT AND IMPROVEMENTS, NET Property and equipment, net consists of the following as of December 31, 2021: Computers and equipment $ 67,077 Furniture and fixtures 33,063 Leasehold improvements 19,304 Total property, plant, and improvements 119,444 Accumulated depreciation 22,041 Net property, plant and improvements $ 97,403 Effective August 1, 2020, 20 third third 18 9 December 31, 2020. no July 9, 2021. Depreciation expense was $22,164 and $10,724 for the years ended December 31, 2021 2020, |
Note 7 - Advances to CEN Biotec
Note 7 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Advances to Related Party [Text Block] | NOTE 7 ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL On December 21, 2020, 17 December 31, 2020. December 31, 2021. not April 19, 2021. April 12, 2021. 402 2002, May 6, 2021, May 6, 2021. not December 31, 2021. At December 31, 2021 2020, 17. 25 Bahige (Bill) Chaaban, Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not not |
Note 8 - Intangible Assets
Note 8 - Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 8 INTANGIBLE ASSETS Lighting Patent On September 12, 2016, August 31, 2016, The patent remained in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 not In March 2018, December 31, 2020, On October 7, 2021, five October 7, 2021 four million 9, The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible assets consists of the following as of December 31: 2021 2020 Estimated Lighting patent $ 6,797,000 $ 6,797,000 16 Product technology 276,080 - n/a Customer relationships 149,872 - 7 Capitalized software development costs 105,730 - n/a Trade names 23,664 - 3 Total identifiable intangible assets 7,352,346 6,797,000 Less: Accumulated amortization 2,280,315 1,840,853 Net $ 5,072,031 $ 4,956,147 As of December 31, 2021 2020, no 2031, 2032. July 9, 2021 2023, 2024, 2025 2026, 2028. not not |
Note 9 - Loans Payable
Note 9 - Loans Payable | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | NOTE 9 LOANS PAYABLE Loans payable consist of the following at December 31: 2021 2020 Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713 7 $ 871,398 $ - Loans payable in default to multiple private investors bearing an interest at rates of up to 12 June 2018 May 2021 592,395 - Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 April 16, 2022 100,000 100,000 Loan payable to Global Holdings International, LLC, which bears interest at 15 June 30, 2016 75,000 75,000 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Mortgage payable to ARG & Pals, Inc., for the original amount of CAD 385,000 22 September 21, 2021 - 302,379 Total loans payable (all current) $ 1,688,793 $ 527,379 During 2020, June 30, 2016 no November 2020. 2002, 2002, 24, 2 June 30, 2016, 2 405 20 40 1 During both 2021 2020, December 31, 2021, one not 2021 2020, During 2021, no |
Note 10 - Loans Payable- Relate
Note 10 - Loans Payable- Related Party | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Loans Payable to Related Party [Text Block] | NOTE 10 LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following at December 31: 2021 2020 Loan payable in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12 August 17, 2020 $ 1,388,122 $ - Loans payable in default to a former director of Creative, former parent company, bear interest at 10 December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8 October 2, 2019 300,000 300,000 Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 198,660 10 December 31, 2018 237,019 236,854 Loan payable to the spouse of Joseph Byrne, a 5 4,000 April 16, 2022 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 April 16, 2022 75,000 75,000 Loan payable to Joseph Byrne, a 5 2,000 - 50,000 Total loans payable - related party (all current) $ 2,701,641 $ 1,363,354 Attributable related party accrued interest was $671,665 and $568,969 as of December 31, 2021 2020, 2021 2020, During both 2021 2020, 2021 2020, |
Note 11 - Convertible Notes
Note 11 - Convertible Notes | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | NOTE 11 CONVERTIBLE NOTES Convertible notes payable consists of the following at December 31: 2021 2020 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5 363,767 May 2018 October 2021 $ 576,472 $ 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5 550,965 June 2022 December 2022 145,000 - Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7 335,833 - 867,641 Total convertible notes payable 721,472 6,730,448 Less unamortized debt discount 78,142 - Total convertible notes payable, net of unamortized debt discount 643,330 6,730,448 Less current portion 643,330 6,652,448 Convertible notes payable, less current portion $ - $ 78,000 The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during 2021 2021 2020. may During 2021, no 2020. During 2021, no 2020. As of April 14, 2022, |
Note 12 - Convertible Notes - R
Note 12 - Convertible Notes - Related Parties | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Long-term Convertible Notes Related Party [Text Block] | NOTE 12 CONVERTIBLE NOTES - RELATED PARTY Convertible notes - related party consists of the following at December 31: 2021 2020 Convertible notes, in default, due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12 76,123 August 17, 2020 $ 121,796 $ 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5 94,488 May 24, 2022 48,000 - Convertible note, in default, due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12 867,576 August 17, 2020 - 1,388,122 Convertible notes due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5 548,980 - 878,368 Convertible note due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5 12,500 - 20,000 Total convertible notes payable – related parties 169,796 2,558,681 Less unamortized debt discount 7,157 - Total convertible notes payable - related parties (all current) $ 162,639 $ 2,558,681 Attributable related party accrued interest was $1,201,790 and $1,046,911 as of December 31, 2021 2020, 2021 2020, The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during 2021 2021 2020. may During 2021, As of April 14, 2022, |
Note 13 - CEBA Loan Payable
Note 13 - CEBA Loan Payable | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Loan Payable , Disclosure [Text Block] | NOTE 13 CEBA LOAN PAYABLE The Canada Emergency Business Account (“CEBA”) loan payable of $31,552 (CAD 40,000) as of December 31, 2021 December 2022 not December 31, 2023, December 2025. |
Note 14 - Governmental Assistan
Note 14 - Governmental Assistance | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Governmental Assistance Disclosure [Text Block] | NOTE 14 GOVERNMENTAL ASSISTANCE The Canadian government enacted the Canada Emergency Wage Subsidy (“CEWS”) and Canada Emergency Rent Subsidy (“CERS”) in 2020 19 2021 December 31, 2021 |
Note 15 - Income Taxes
Note 15 - Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 15 INCOME TAXES The Company has elected to file separate Canadian income tax returns for CEN (growth) and for CCM (digital). Growth: As of December 31, 2021, may 20 2034. may not not December 31: 2021 2020 Deferred tax asset - net operating losses $ 8,300,000 $ 3,400,000 Deferred tax asset valuation allowance (8,300,000 ) (3,400,000 ) Net deferred tax asset $ - $ - The change in the valuation allowance amounted to $4,900,000 and $3,400,000 for the years ended December 31, 2021 2020, Digital: The tax benefit for CCM income taxes consists of the following components: December 31, 2021 Current $ (33,621 ) Deferred (2,735 ) Net income tax benefit $ (36,356 ) The net deferred income tax asset presented in the consolidated balance sheets is comprised of the following at: December 31, 2021 Deferred tax assets SR&ED credits $ 39,464 Deferred tax liabilities Property and equipment (11,357 ) Intangible assets, including goodwill (25,387 ) Total deferred tax liabilities (36,744 ) Net deferred tax asset $ 2,720 A reconciliation of the income tax benefit and the amount computed by applying the statutory Canadian federal income tax rate to CEN’s and CCM’s income before income tax benefit for the year ended December 31 2021 2020 Growth Digital Total Growth Digital Total Income tax (benefit) expense at statutory rate of 26.5 $ (5,020,280 ) $ 1,177 $ (5,019,103 ) $ 3,776,156 $ - $ 3,776,156 Valuation allowance 5,020,280 - 5,020,280 (3,776,156 ) - (3,776,156 ) SR&ED credits - (19,198 ) (19,198 ) - - - Other - (18,335 ) (18,335 ) - - - Income tax benefit $ - $ (36,356 ) $ (36,356 ) $ - $ - $ - Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of December 31, 2021, no no no 2018. |
Note 16 - Shareholders' Deficit
Note 16 - Shareholders' Deficit / Stock Activity | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 16 SHAREHOLDERS DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value. As of December 31, 2021, one 9, not As of December 31, 2021, |
Note 17 - Related Party Transac
Note 17 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 17 RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 10 12. A loan totaling $17,901 was made to Emergence Global as of December 31, 2020. July 2017 November 13, 2019. May 6, 2021, 7. There are advances of $1,299,328 and $1,179,328 to CEN Ukraine as of December 31, 2021 2020, 7. December 3, 2017, December 14, 2017, not April 14, 2022, not not During the years ended December 31, 2021 2020, December 31, 2021 2020, During the year ended December 31, 2021, During 2017, 10 2017 2026. No December 31, 2021. 25 As of December 31, 2021 2020, During 2021, December 31, 2021, As of December 31, 2021, |
Note 18 - Lease (Including Rela
Note 18 - Lease (Including Related Parties) | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | NOTE 18 LEASE (INCLUDING RELATED PARTIES) The Company currently leases certain facilities and equipment under noncancelable operating lease agreements that expire at various dates through 2024. The Company also leased office space in Windsor, Ontario from RN Holdings Ltd. Under the lease agreement effective October 1, 2017, September 2022, August 1, 2020, no August 1, 2020. August 1, 2020 April 14, 2022, not December 31, 2021 December 31, 2021 2020 2021 2020, The operating lease liability as of December 31, 2021 2020 2021 2020, Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased a property at 20 January 2017 4,000 five third October 2019. August 1, 2020, August 1, 2020 2020, The following is a schedule of future annual minimum rental payments required under operating leases with initial or remaining noncancelable lease terms in excess of one 12 December 31: Amount 2022 $ 119,543 2023 90,325 2024 61,897 2025 32,088 2026 32,088 Thereafter 24,066 Total lease payments $ 360,007 Less imputed interest 49,336 Present value of lease liability $ 310,671 |
Note 19 - Stock Based Compensat
Note 19 - Stock Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | NOTE 19 STOCK BASED COMPENSATION Adoption of Equity Compensation Plan On November 29, 2017, 2017 On April 2, 2021, 2021 “2021 2021 Equity Compensation Grants On November 30, 2017, one 36 November 2020. 36 November 2020. On April 17, 2020, three On August 27, 2020 September 25, 2020, two On April 2, 2021, 12 On July 13, 2021, two Employment Agreements On November 30, 2017, four ☐ Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ☐ Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 November 2020. November 13, 2019, April 2, 2020, not ☐ Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ☐ Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 36 November 2020. On May 16, 2019, one 36 May 2022. On December 6, 2021, 36 December 2024. On April 2, 2021, On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021 June 25, 2021, 2021 Restricted Stock Awards Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants. The total grant-date fair value of the restricted shares granted through employment agreements and equity compensation grants was $29,885,063 and $13,013,241 as of December 31, 2021 2020, 2021 2020, April 5, 2021 April 5, 2021, With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally three During 2021 2020, 2021 2020, Compensation expense, broken out by allocation, recognized in connection with the restricted stock awards was as follows for the years ended December 31: 2021 2020 Stock Based Compensation $ 15,390,822 $ 746,300 Professional fees 1,172,000 279,000 Total $ 16,562,822 $ 1,025,300 Non-vested restricted stock award activity for the years ended December 31, 2021 2020 Number of Weighted- Weighted- Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,987,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2020 425,000 $ 1.01 1.50 Granted 15,059,291 1.12 - Vested (13,559,291 ) 1.22 - Forfeited - - - Non-vested at December 31, 2021 1,925,000 $ 0.38 2.84 The fair value of the restricted stock grants was based on the valuation of a third April 5, 2021. April 5, 2021, December 31, 2021, December 2024. |
Note 20 - Other Receivable
Note 20 - Other Receivable | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | NOTE 20 In May 2017, June 30, 2018 February 16, 2021, December 31, 2021 ( No December 31, 2020. may 5 |
Note 21 - Net (Loss) Income Per
Note 21 - Net (Loss) Income Per Share | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | NOTE 21 NET (LOSS) INCOME PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of December 31, 2021. 2020, 8, December 31, 2021 2020 2021 2020 Convertible debt 1,085,343 - Tesla agreement - 1,000,000 The following table shows the computation of basic and diluted earnings per share for 2020: Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 14,249,645 27,264,072 $ 0.52 Effect of Dilutive Securities Convertible debt 585,392 5,468,438 Diluted EPS Income available to common stockholders with assumed conversions $ 14,835,037 32,732,510 $ 0.45 |
Note 22 - Fair Value Disclosure
Note 22 - Fair Value Disclosures | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 22 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2021: Cash and cash equivalents $ 193,198 $ - $ 193,198 $ - $ 193,198 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 643,330 $ - $ - $ 1,890,736 $ 1,890,736 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 31,552 $ - $ - $ 31,552 $ 31,552 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3 rd April 5, 2021. April 5, 2021, 3 1 2021. October 7, 2021, 8. |
Note 23 - Segment Information
Note 23 - Segment Information | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | NOTE 23 SEGMENT INFORMATION As described in Note 5, July 9, 2021. two Segment information: Year Ended December 31, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 626,867 $ - $ - Operating (loss) income (19,042,415 ) 4,874 (2,543,730 ) - Depreciation expense - 22,164 10,724 - Amortization expense 424,812 14,731 424,812 - Interest income 394 110 6,400 - Interest expense 846,749 - 3,676,858 - Income tax benefit - 36,356 - - Capital expenditures - 23,213 - - Segment assets to total assets as of December 31: 2021 2020 Growth $ 5,900,371 $ 6,314,142 Digital 2,540,428 - Total assets $ 8,440,799 $ 6,314,142 All goodwill included in the consolidated balance sheets is attributable to the Digital segment. |
Note 24 - Contingency
Note 24 - Contingency | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 24 CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 10 May 4, 2016 5 not |
Note 25 - Subsequent Events
Note 25 - Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 25 SUBSEQUENT EVENTS Our operating plans, business, financial condition and operating results may February 2022, March 31, 2022, Subsequent to December 31, 2021, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Consolidation CEN’s consolidated financial statements include the accounts of CEN, CCM, and Eastern Starr (collectively, the “Company”). CCM is a Windsor, Ontario based digital marketing, and e-commerce company. CCM’s purpose is to develop, market and sell various digital products. Additionally, CCM will provide in-house IT support functions for CEN’s activities. Eastern Starr’s purpose is to facilitate future growth opportunities in the LED lighting sector. All material intercompany transactions are eliminated in consolidation. |
Basis of Accounting, Policy [Policy Text Block] | Basis of Accounting The Company’s consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and disclosure of contingent assets and liabilities at the date of the financial statements (including intangible assets and goodwill), and the reported amounts of revenues and expenses during the reporting period, including stock-based compensation. Accordingly, actual results may |
Revenue from Contract with Customer [Policy Text Block] | Revenue from Contracts with Customers The Company has agreements with third no not not not The Company derived approximately 99% of its revenue from one customer during the year ended December 31, 2021. December 31, 2021 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents For purposes of the consolidated balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three |
Accounts Receivable [Policy Text Block] | Accounts Receivable Accounts receivable are customer obligations due under normal trade terms generally requiring payment within 30 60 no not |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are recorded at cost. Major improvements and renewals are capitalized while ordinary maintenance and repairs are expensed. Management reviews these assets for impairment whenever events or changes in circumstances indicate the related carrying amount may not See Note 6 2020 |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible Assets Trade Names and Customer Relationships may not Product Technology and Capitalized Software Development Costs 985 20 25, Costs of Software to Be Sold, Leased or Marketed not December 31, 2021. Lighting Patent may not may not |
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] | Goodwill Goodwill arising from business combinations represents the excess of purchase consideration exchanged by the Company over the estimated fair value of the net assets of acquired businesses. The Company evaluates goodwill for impairment on an annual basis. In completing this evaluation, the Company considers the profitability of Clear Com Media, Inc. and compares its best estimate of future cash flows with the net carrying value of goodwill. |
Income Tax, Policy [Policy Text Block] | Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Foreign denominated monetary assets and liabilities of the Company are translated at the rate of exchange prevailing at the consolidated balance sheet date. Other assets and liabilities denominated in foreign currencies are translated at the exchange rates prevailing when the assets were acquired or the liabilities incurred. Sales and expenses are translated at the average exchange rate over the reporting period. Transaction gains or losses are included in the determination of net (loss) income. The functional currency of CCM is the Canadian dollar. The accounts of CCM were translated to United States dollars equivalents at exchange rates as follows: balance sheet assets and liabilities were converted at period-end rates, equity at historical rates, and income statement accounts at average rates for the period. The resulting translation gain or loss is reflected in other comprehensive loss and accumulated other comprehensive loss in the consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ deficit, respectively. |
Share-based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, Compensation Stock Compensation 718 718 |
Earnings Per Share, Policy [Policy Text Block] | (Loss) Income per Share Net (loss) income per common share is computed pursuant to Accounting Standards Codification (ASC) 260 10 45. 2021, not 21. |
Lessee, Leases [Policy Text Block] | Leases The Company accounts for leases pursuant to ASC Topic 842, Leases not 2020, 20 18. |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassification Certain amounts as reported in the 2020 2021 |
Note 5 - Acquisition of Clear_2
Note 5 - Acquisition of Clear Com Media, Inc. (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Cash $ 259,470 Accounts receivable 210,536 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 456,855 Current financial liabilities (344,591 ) Other long-term liabilities (140,078 ) Total identifiable net assets 784,643 Goodwill 1,335,357 Net assets acquired $ 2,120,000 |
Business Acquisition, Pro Forma Information [Table Text Block] | Years Ended December 31, 2021 December 31, 2020 Revenue $ 1,305,985 $ 1,242,676 Operating expenses 20,437,863 3,720,279 Loss from operations (19,131,878 ) (2,477,603 ) Other income, net 57,949 16,950,653 (Loss) income before income taxes (19,073,929 ) 14,473,050 Income tax expense (61,032 ) 32,892 Net (loss) income $ (19,012,897 ) $ 14,440,158 Net (Loss) Income Per Share Basic $ (0.43 ) $ 0.46 Diluted $ (0.43 ) $ 0.39 Weighted Average Number of Shares Outstanding Basic 44,488,649 31,264,072 Diluted 44,488,649 36,732,510 |
Note 6 - Property, Plant and _2
Note 6 - Property, Plant and Improvements, Net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | Computers and equipment $ 67,077 Furniture and fixtures 33,063 Leasehold improvements 19,304 Total property, plant, and improvements 119,444 Accumulated depreciation 22,041 Net property, plant and improvements $ 97,403 |
Note 8 - Intangible Assets (Tab
Note 8 - Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | 2021 2020 Estimated Lighting patent $ 6,797,000 $ 6,797,000 16 Product technology 276,080 - n/a Customer relationships 149,872 - 7 Capitalized software development costs 105,730 - n/a Trade names 23,664 - 3 Total identifiable intangible assets 7,352,346 6,797,000 Less: Accumulated amortization 2,280,315 1,840,853 Net $ 5,072,031 $ 4,956,147 |
Note 9 - Loans Payable (Tables)
Note 9 - Loans Payable (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | 2021 2020 Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713 7 $ 871,398 $ - Loans payable in default to multiple private investors bearing an interest at rates of up to 12 June 2018 May 2021 592,395 - Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 April 16, 2022 100,000 100,000 Loan payable to Global Holdings International, LLC, which bears interest at 15 June 30, 2016 75,000 75,000 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Mortgage payable to ARG & Pals, Inc., for the original amount of CAD 385,000 22 September 21, 2021 - 302,379 Total loans payable (all current) $ 1,688,793 $ 527,379 |
Note 10 - Loans Payable- Rela_2
Note 10 - Loans Payable- Related Party (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Loans Payable to Related Party [Table Text Block] | 2021 2020 Loan payable in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12 August 17, 2020 $ 1,388,122 $ - Loans payable in default to a former director of Creative, former parent company, bear interest at 10 December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8 October 2, 2019 300,000 300,000 Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 198,660 10 December 31, 2018 237,019 236,854 Loan payable to the spouse of Joseph Byrne, a 5 4,000 April 16, 2022 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 April 16, 2022 75,000 75,000 Loan payable to Joseph Byrne, a 5 2,000 - 50,000 Total loans payable - related party (all current) $ 2,701,641 $ 1,363,354 |
Note 11 - Convertible Notes (Ta
Note 11 - Convertible Notes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | 2021 2020 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5 363,767 May 2018 October 2021 $ 576,472 $ 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5 550,965 June 2022 December 2022 145,000 - Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7 335,833 - 867,641 Total convertible notes payable 721,472 6,730,448 Less unamortized debt discount 78,142 - Total convertible notes payable, net of unamortized debt discount 643,330 6,730,448 Less current portion 643,330 6,652,448 Convertible notes payable, less current portion $ - $ 78,000 |
Note 12 - Convertible Notes -_2
Note 12 - Convertible Notes - Related Parties (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Convertible Notes Payable to Related Party [Table Text Block] | 2021 2020 Convertible notes, in default, due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12 76,123 August 17, 2020 $ 121,796 $ 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5 94,488 May 24, 2022 48,000 - Convertible note, in default, due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12 867,576 August 17, 2020 - 1,388,122 Convertible notes due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5 548,980 - 878,368 Convertible note due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5 12,500 - 20,000 Total convertible notes payable – related parties 169,796 2,558,681 Less unamortized debt discount 7,157 - Total convertible notes payable - related parties (all current) $ 162,639 $ 2,558,681 |
Note 15 - Income Taxes (Tables)
Note 15 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2021 2020 Deferred tax asset - net operating losses $ 8,300,000 $ 3,400,000 Deferred tax asset valuation allowance (8,300,000 ) (3,400,000 ) Net deferred tax asset $ - $ - December 31, 2021 Deferred tax assets SR&ED credits $ 39,464 Deferred tax liabilities Property and equipment (11,357 ) Intangible assets, including goodwill (25,387 ) Total deferred tax liabilities (36,744 ) Net deferred tax asset $ 2,720 |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | December 31, 2021 Current $ (33,621 ) Deferred (2,735 ) Net income tax benefit $ (36,356 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2021 2020 Growth Digital Total Growth Digital Total Income tax (benefit) expense at statutory rate of 26.5 $ (5,020,280 ) $ 1,177 $ (5,019,103 ) $ 3,776,156 $ - $ 3,776,156 Valuation allowance 5,020,280 - 5,020,280 (3,776,156 ) - (3,776,156 ) SR&ED credits - (19,198 ) (19,198 ) - - - Other - (18,335 ) (18,335 ) - - - Income tax benefit $ - $ (36,356 ) $ (36,356 ) $ - $ - $ - |
Note 18 - Lease (Including Re_2
Note 18 - Lease (Including Related Parties) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Amount 2022 $ 119,543 2023 90,325 2024 61,897 2025 32,088 2026 32,088 Thereafter 24,066 Total lease payments $ 360,007 Less imputed interest 49,336 Present value of lease liability $ 310,671 |
Note 19 - Stock Based Compens_2
Note 19 - Stock Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | 2021 2020 Stock Based Compensation $ 15,390,822 $ 746,300 Professional fees 1,172,000 279,000 Total $ 16,562,822 $ 1,025,300 |
Nonvested Restricted Stock Shares Activity [Table Text Block] | Number of Weighted- Weighted- Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 387,500 0.72 - Vested (1,987,500 ) 0.70 - Forfeited - - - Non-vested at December 31, 2020 425,000 $ 1.01 1.50 Granted 15,059,291 1.12 - Vested (13,559,291 ) 1.22 - Forfeited - - - Non-vested at December 31, 2021 1,925,000 $ 0.38 2.84 |
Note 21 - Net (Loss) Income P_2
Note 21 - Net (Loss) Income Per Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | 2021 2020 Convertible debt 1,085,343 - Tesla agreement - 1,000,000 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 14,249,645 27,264,072 $ 0.52 Effect of Dilutive Securities Convertible debt 585,392 5,468,438 Diluted EPS Income available to common stockholders with assumed conversions $ 14,835,037 32,732,510 $ 0.45 |
Note 22 - Fair Value Disclosu_2
Note 22 - Fair Value Disclosures (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Fair Value, by Balance Sheet Grouping [Table Text Block] | Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2021: Cash and cash equivalents $ 193,198 $ - $ 193,198 $ - $ 193,198 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 643,330 $ - $ - $ 1,890,736 $ 1,890,736 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 31,552 $ - $ - $ 31,552 $ 31,552 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - |
Note 23 - Segment Information (
Note 23 - Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Year Ended December 31, 2021 2020 Growth Digital Growth Digital Revenue $ - $ 626,867 $ - $ - Operating (loss) income (19,042,415 ) 4,874 (2,543,730 ) - Depreciation expense - 22,164 10,724 - Amortization expense 424,812 14,731 424,812 - Interest income 394 110 6,400 - Interest expense 846,749 - 3,676,858 - Income tax benefit - 36,356 - - Capital expenditures - 23,213 - - |
Reconciliation of Assets from Segment to Consolidated [Table Text Block] | 2021 2020 Growth $ 5,900,371 $ 6,314,142 Digital 2,540,428 - Total assets $ 8,440,799 $ 6,314,142 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Research and Development Expense, Total | $ 0 | $ 0 |
Lighting Patent [Member] | ||
Finite-Lived Intangible Asset, Useful Life (Year) | 16 years | |
Minimum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 2 years | |
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years | |
Maximum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 7 years | |
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||
Number of Major Customers | 1 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member] | ||
Concentration Risk, Percentage | 99.00% |
Note 4 - Going Concern Uncert_2
Note 4 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (45,964,183) | $ (27,060,527) |
Note 5 - Acquisition of Clear_3
Note 5 - Acquisition of Clear Com Media, Inc. (Details Textual) - USD ($) | Sep. 30, 2021 | Jul. 09, 2021 | Jul. 09, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Stock Issued During Period, Value, Acquisitions | $ 2,120,000 | ||||
Finite-Lived Intangible Assets, Accumulated Amortization | 2,280,315 | $ 1,840,853 | |||
Amortization of Intangible Assets, Total | $ 439,543 | $ 424,812 | |||
Minimum [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years | ||||
Maximum [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | ||||
Clear Com Media, Inc [Member] | |||||
Stock Issued During Period, Shares, Acquisitions (in shares) | 4,000,000 | ||||
Stock Issued During Period, Value, Acquisitions | $ 2,120,000 | ||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable | $ 8,000 | ||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles | (168,000) | ||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities | 23,000 | ||||
Goodwill, Purchase Accounting Adjustments | $ 184,000 | ||||
Finite-lived Intangible Assets Acquired | $ 456,855 | ||||
Clear Com Media, Inc [Member] | General and Administrative Expense [Member] | |||||
Business Combination, Acquisition Related Costs | $ 80,000 | ||||
Clear Com Media, Inc [Member] | Minimum [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years | ||||
Clear Com Media, Inc [Member] | Maximum [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | ||||
Clear Com Media, Inc [Member] | Scenario, Adjustment [Member] | |||||
Finite-Lived Intangible Assets, Accumulated Amortization | $ 15,000 | ||||
Amortization of Intangible Assets, Total | $ 15,000 |
Note 5 - Acquisition of Clear_4
Note 5 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Goodwill | $ 1,314,134 | $ 0 |
Clear Com Media, Inc [Member] | ||
Cash | 259,470 | |
Accounts receivable | 210,536 | |
Property and equipment | 97,911 | |
Other assets | 244,540 | |
Identifiable intangibles | 456,855 | |
Current financial liabilities | (344,591) | |
Other long-term liabilities | (140,078) | |
Total identifiable net assets | 784,643 | |
Goodwill | 1,335,357 | |
Net assets acquired | $ 2,120,000 |
Note 5 - Acquisition of Clear_5
Note 5 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details) - Clear Com Media, Inc [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | $ 1,305,985 | $ 1,242,676 |
Operating expenses | 20,437,863 | 3,720,279 |
Loss from operations | (19,131,878) | (2,477,603) |
Other income, net | 57,949 | 16,950,653 |
(Loss) income before income taxes | (19,073,929) | 14,473,050 |
Income tax expense | (61,032) | 32,892 |
Net (loss) income | $ (19,012,897) | $ 14,440,158 |
Basic (in dollars per share) | $ (0.43) | $ 0.46 |
Diluted (in dollars per share) | $ (0.43) | $ 0.39 |
Diluted (in shares) | 44,488,649 | 36,732,510 |
Note 6 - Property, Plant and _3
Note 6 - Property, Plant and Improvements, Net (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Proceeds from Sale of Property, Plant, and Equipment, Total | $ 0 | $ 1,801 |
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | 0 | (135,600) |
Depreciation, Total | $ 22,164 | $ 10,724 |
Note 6 - Property, Plant and _4
Note 6 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Property, plant and equipment, gross | $ 119,444 | |
Total property, plant, and improvements | 119,444 | |
Accumulated depreciation | 22,041 | |
Property and equipment, net | 97,403 | $ 0 |
Computer Equipment [Member] | ||
Property, plant and equipment, gross | 67,077 | |
Total property, plant, and improvements | 67,077 | |
Furniture and Fixtures [Member] | ||
Property, plant and equipment, gross | 33,063 | |
Total property, plant, and improvements | 33,063 | |
Leasehold Improvements [Member] | ||
Property, plant and equipment, gross | 19,304 | |
Total property, plant, and improvements | $ 19,304 |
Note 7 - Advances to CEN Biot_2
Note 7 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual) - USD ($) | May 06, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 02, 2017 |
Notes Receivable, Related Parties, Current | $ 0 | $ 17,901 | ||
Emergence Global [Member] | ||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.82 | |||
Former CEO [Member] | ||||
Ownership Percentage | 5.00% | |||
CEN Biotech Ukraine [Member] | ||||
Notes Receivable, Related Parties, Current | $ 17,901 | |||
Due from Related Parties, Total | $ 1,299,328 | 1,179,328 | ||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | |||
CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member] | ||||
Ownership Percentage | 49.00% | |||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||
Emergence Global [Member] | ||||
Notes Receivable, Related Parties, Current | $ 17,901 | |||
Notes Receivable, Original Amount Converted to Common Stock | $ 17,901 | |||
Notes Receivable, Converted Instrument, Shares Received as Payment (in shares) | 21,830 |
Note 8 - Intangible Assets (Det
Note 8 - Intangible Assets (Details Textual) - USD ($) | Oct. 07, 2021 | Sep. 12, 2016 | Sep. 30, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2021 | Jul. 09, 2021 |
Development of Acquired Technology, Annual Compensation for Specialist | $ 200,000 | ||||||
Contingent Consideration Classified as Equity, Fair Value Disclosure | $ 1,380,000 | ||||||
Gain (Loss) on Settlement of Lighting Patent Purchase, Including Shares Issued | $ (1,331,814) | 0 | |||||
Impairment of Real Estate | 0 | $ 0 | |||||
Lighting Patent [Member] | |||||||
Finite-Lived Intangible Asset, Expected Amortization, Year One | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven | $ 283,215 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Seven | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Two | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Three | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Six | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eight | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Nine | 424,812 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Ten | $ 424,812 | ||||||
Customers Relationships and Trade Names [Member] | |||||||
Finite-Lived Intangible Asset, Expected Amortization, Year One | $ 29,300 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 25,400 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 21,400 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Seven | 32,100 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Two | 29,300 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Three | 29,300 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Six | 21,400 | ||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eight | $ 32,100 | ||||||
Tesla Digital Transaction [Member] | |||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 5,000,000 | ||||||
Stock Issued During Period, Value, Purchase of Assets | $ 2,042,500 | ||||||
Stock Issued During Period, Purchase of Assets, Expense | 1,634,000 | ||||||
Asset Acquisition, Liabilities Assumed | 302,186 | ||||||
Gain (Loss) on Settlement of Lighting Patent Purchase, Including Shares Issued | $ (1,331,814) | ||||||
Tesla Digital [Member] | |||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 1,000,000 |
Note 8 - Intangible Assets - In
Note 8 - Intangible Assets - Intangible Assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Finite-lived intangible assets, gross | $ 7,352,346 | $ 6,797,000 |
Less: Accumulated amortization | 2,280,315 | 1,840,853 |
Net | 5,072,031 | 4,956,147 |
Lighting Patent [Member] | ||
Finite-lived intangible assets, gross | $ 6,797,000 | 6,797,000 |
Finite-Lived Intangible Asset, Useful Life (Year) | 16 years | |
Technology-Based Intangible Assets [Member] | ||
Finite-lived intangible assets, gross | $ 276,080 | 0 |
Customer Relationships [Member] | ||
Finite-lived intangible assets, gross | $ 149,872 | 0 |
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | |
Computer Software, Intangible Asset [Member] | ||
Finite-lived intangible assets, gross | $ 105,730 | 0 |
Trade Names [Member] | ||
Finite-lived intangible assets, gross | $ 23,664 | $ 0 |
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years |
Note 9 - Loans Payable (Details
Note 9 - Loans Payable (Details Textual) | 12 Months Ended | |
Dec. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | |
Interest Expense, Debt, Total | $ 428,249 | $ 3,233,421 |
Stock Issued During Period, Value, New Issues | 135,166 | 159,300 |
Short-term Loan Payable to Private Investors [Member] | ||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 1,463,793 | |
Debt Instrument, Convertible, Number of Equity Instruments | 677,955 | |
Additional Paid-in Capital [Member] | ||
Stock Issued During Period, Value, New Issues | $ 135,166 | $ 159,300 |
Individual Lenders [Member] | ||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 62,000 | 72,000 |
Stock Issued During Period, Shares, New Issues, Not yet Recognized (in shares) | shares | 10,000 | |
Stock Issued During Period, Value, New Issues, Not yet Recognized | $ 4,012 | |
Interest Expense, Debt, Total | 57,876 | $ 63,720 |
Individual Lenders [Member] | Additional Paid-in Capital [Member] | ||
Stock Issued During Period, Value, New Issues | $ 53,864 | 63,720 |
Global Holdings International, LLC [Member] | ||
Derecognition of Debt, Amount | 9,600,000 | |
Derecognition of Debt, Accrued Interest, Amount | $ 11,579,043 |
Note 9 - Loans Payable - Loans
Note 9 - Loans Payable - Loans Payable (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | $ 1,688,793 | $ 527,379 |
Loan payable | 1,688,793 | 527,379 |
Short-term Loan Payable to Private Investors [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 871,398 | 0 |
Loan payable | 871,398 | 0 |
Short-term Loan Payable to Multiple Investors [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 592,395 | 0 |
Loan payable | 592,395 | 0 |
Second Short-term Loan Payable to an Individual [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 100,000 | 100,000 |
Loan payable | 100,000 | 100,000 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 75,000 | 75,000 |
Loan payable | 75,000 | 75,000 |
Short-term Loan Payable to an Individual [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 50,000 | 50,000 |
Loan payable | 50,000 | 50,000 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 0 | 302,379 |
Loan payable | $ 0 | $ 302,379 |
Note 9 - Loans Payable - Loan_2
Note 9 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Short-term Loan Payable to Private Investors [Member] | ||
Original Amount | $ 1,104,713 | |
Interest Rate | 7.00% | |
Short-term Loan Payable to Multiple Investors [Member] | ||
Interest Rate | 12.00% | 12.00% |
Maturity Date, start | Jun. 1, 2018 | Jun. 1, 2018 |
Maturity Date, end | May 31, 2021 | May 31, 2021 |
Second Short-term Loan Payable to an Individual [Member] | ||
Share Interest (in shares) | 4,000 | 4,000 |
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Interest Rate | 15.00% | 15.00% |
Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
Short-term Loan Payable to an Individual [Member] | ||
Share Interest (in shares) | 2,000 | 2,000 |
Maturity Date | Jul. 16, 2021 | Jul. 16, 2021 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Original Amount | $ 385,000 | |
Interest Rate | 22.00% | |
Maturity Date | Sep. 21, 2021 |
Note 10 - Loans Payable- Rela_3
Note 10 - Loans Payable- Related Party (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Interest Expense, Related Party | $ 418,500 | $ 443,437 |
Stock Issued During Period, Value, New Issues | $ 135,166 | $ 159,300 |
Related Parties Lenders [Member] | ||
Stock Issued During Period, Shares, New Issues (in shares) | 96,000 | 108,000 |
Stock Issued During Period, Value, New Issues | $ 81,302 | $ 95,580 |
Loans Payable to Related Party [Member] | ||
Interest Payable, Related Party | 671,665 | 568,969 |
Interest Expense, Related Party | $ 189,182 | $ 202,640 |
Note 10 - Loans Payable - Relat
Note 10 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Long-term Debt | $ 2,701,641 | $ 1,363,354 |
Mr. Chaaban's Spouse [Member] | ||
Long-term Debt | 1,388,122 | 0 |
Creative Edge [Member] | ||
Long-term Debt | 601,500 | 601,500 |
R&D Labs Canada, Inc [Member] | ||
Long-term Debt | 300,000 | 300,000 |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt | 237,019 | 236,854 |
Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||
Long-term Debt | 100,000 | 100,000 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt | 75,000 | 75,000 |
Joseph Byrne [Member] | ||
Long-term Debt | $ 0 | $ 50,000 |
Note 10 - Loans Payable - Rel_2
Note 10 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) | 12 Months Ended | |||
Dec. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | Dec. 31, 2021CAD ($)shares | Dec. 31, 2020CAD ($)shares | |
Joseph Byrne [Member] | ||||
Related Party Interest | 5.00% | 5.00% | ||
Loans Payable to Related Party [Member] | Mr. Chaaban's Spouse [Member] | ||||
Interest Rate | 12.00% | 12.00% | ||
Maturity Date | Aug. 17, 2020 | |||
Loans Payable to Related Party [Member] | Creative Edge [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member] | ||||
Interest Rate | 8.00% | 8.00% | 8.00% | 8.00% |
Maturity Date | Oct. 2, 2019 | Oct. 2, 2019 | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Original Amount | $ 198,660 | $ 198,660 | $ 48,630 | $ 48,630 |
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||||
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 | ||
Share Interest (in shares) | 4,000 | 4,000 | 4,000 | 4,000 |
Related Party Interest | 5.00% | 5.00% | 5.00% | 5.00% |
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member] | ||||
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 | ||
Share Interest (in shares) | 3,000 | 3,000 | 3,000 | 3,000 |
Loans Payable to Related Party [Member] | Joseph Byrne [Member] | ||||
Share Interest (in shares) | 2,000 | 2,000 | ||
Related Party Interest | 5.00% | 5.00% |
Note 11 - Convertible Notes (De
Note 11 - Convertible Notes (Details Textual) | Apr. 14, 2022USD ($) | Dec. 31, 2021USD ($)shares | Dec. 31, 2020USD ($) |
Conversion of Convertible Notes into Common Stock [Member] | |||
Debt Conversion, Original Debt, Amount | $ 5,173,785 | ||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 3,488,883 | ||
Debt Conversion, Accrued Interest, Amount | $ 78,893 | ||
Stock Issued During Period, Shares, Settlement of Accrued Interest (in shares) | shares | 94,357 | ||
Convertible Debt Payable to Non-related Party [Member] | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 180,098 | ||
Convertible Debt [Member] | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 198,239 | $ 0 | |
Debt Instrument, Convertible, Number of Equity Instruments | 914,732 | ||
Convertible Debt [Member] | Forecast [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 363,767 | ||
Debt Instrument, Debt Default, Amount | $ 576,472 |
Note 11 - Convertible Notes - C
Note 11 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Long-term Debt, gross | $ 721,472 | $ 6,730,448 |
Less unamortized debt discount | 78,142 | 0 |
Long-term Debt | 643,330 | 6,730,448 |
Less current portion | 643,330 | 6,652,448 |
Convertible notes payable, less current portion | 0 | 78,000 |
Convertible Notes 1[Member] | ||
Long-term Debt, gross | 576,472 | 5,862,807 |
Convertible Notes 2 [Member] | ||
Long-term Debt, gross | 145,000 | 0 |
Convertible Notes 3 [Member] | ||
Long-term Debt, gross | $ 0 | $ 867,641 |
Note 11 - Convertible Notes -_2
Note 11 - Convertible Notes - Convertible Notes (Details) (Parentheticals) - Convertible Debt [Member] | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020USD ($) | |
Conversion Rights | 914,732 | |
Convertible Notes 1[Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 363,767 | 363,767 |
Maturity Date, start | May 1, 2018 | May 1, 2018 |
Maturity Date, end | Oct. 31, 2021 | Oct. 31, 2021 |
Convertible Notes 2 [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 550,965 | 550,965 |
Maturity Date, start | Jun. 30, 2022 | |
Maturity Date, end | Dec. 31, 2022 | |
Convertible Notes 3 [Member] | ||
Interest Rate | 7.00% | |
Conversion Rights | 335,833 | |
Original Amount | $ 1,104,713 |
Note 12 - Convertible Notes -_3
Note 12 - Convertible Notes - Related Parties (Details Textual) | Apr. 14, 2022USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) |
Interest Expense, Related Party | $ 418,500 | $ 443,437 | |
Convertible Debt Payable to Related Party [Member] | |||
Interest Payable, Related Party | 1,201,790 | 1,046,911 | |
Interest Expense, Related Party | 229,318 | 240,797 | |
Debt Instrument, Convertible, Beneficial Conversion Feature | 18,141 | 0 | |
Long-term Debt, Total | $ 162,639 | $ 2,558,681 | |
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 76,123 | 76,123 | |
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 170,611 | ||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Forecast [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 76,123 | ||
Debt Instrument, Debt Default, Amount | $ 121,796 | ||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Joseph Byrne [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 63,997 | ||
Long-term Debt, Total | $ 102,395 |
Note 12 - Convertible Notes Pay
Note 12 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Long-term Debt, gross | $ 169,796 | $ 2,558,681 |
Less unamortized debt discount | 7,157 | 0 |
Long-term Debt | 162,639 | 2,558,681 |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt, gross | 0 | 1,388,122 |
Joseph Byrne [Member] | ||
Long-term Debt, gross | 121,796 | 224,191 |
Jeff Thomas [Member] | ||
Long-term Debt, gross | 48,000 | 0 |
Director, Harold Aubrey de Lavenu [Member] | ||
Long-term Debt, gross | 0 | 878,368 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt, gross | 0 | 48,000 |
Brother of Director Ameen Ferris [Member] | ||
Long-term Debt, gross | $ 0 | $ 20,000 |
Note 12 - Convertible Notes P_2
Note 12 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member] | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Bill Chaaban, President of Cen Biotech [Member] | ||
Interest Rate | 12.00% | |
Conversion Rights | 867,576 | |
Maturity Date | Aug. 17, 2020 | |
Joseph Byrne [Member] | ||
Interest Rate | 12.00% | 12.00% |
Conversion Rights | 76,123 | 76,123 |
Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
Jeff Thomas [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 94,488 | |
Maturity Date | May 24, 2022 | |
Director, Harold Aubrey de Lavenu [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 548,980 | |
Director, Alex Tarrabain [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 30,000 | |
Brother of Director Ameen Ferris [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 12,500 |
Note 13 - CEBA Loan Payable (De
Note 13 - CEBA Loan Payable (Details Textual) | Dec. 31, 2022 | Dec. 31, 2021USD ($) | Dec. 31, 2021CAD ($) | Dec. 31, 2020USD ($) |
Loans Payable, Noncurrent, Total | $ 31,552 | $ 0 | ||
Canada Emergency Business Account Loan Payable [Member] | Unsecured Debt [Member] | Royal Bank of Canada [Member] | ||||
Loans Payable, Noncurrent, Total | 31,552 | $ 40,000 | ||
Debt Instrument, Increase in Principle Balance If Loan Is Not Paid | $ 15,776 | $ 20,000 | ||
Canada Emergency Business Account Loan Payable [Member] | Unsecured Debt [Member] | Royal Bank of Canada [Member] | Forecast [Member] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% |
Note 14 - Governmental Assist_2
Note 14 - Governmental Assistance (Details Textual) | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Clear Com Media, Inc [Member] | |
Proceeds from Governmental Assistance | $ 171,078 |
Note 15 - Income Taxes (Details
Note 15 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards, Total | $ 31,400,000 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 4,900,000 | $ 3,400,000 |
Note 15 - income Taxes - Schedu
Note 15 - income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax asset - net operating losses | $ 8,300,000 | $ 3,400,000 |
Deferred tax asset valuation allowance | (8,300,000) | (3,400,000) |
Net deferred tax asset | 0 | $ 0 |
Deferred tax assets | ||
SR&ED credits | 39,464 | |
Deferred tax liabilities | ||
Property and equipment | (11,357) | |
Intangible assets, including goodwill | (25,387) | |
Total deferred tax liabilities | (36,744) | |
Net deferred tax asset | $ 2,720 |
Note 15 - Income Taxes - The Ta
Note 15 - Income Taxes - The Tax Benefit for CCM Income Taxes (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Current | $ (33,621) | |
Deferred income tax benefit | (2,735) | $ 0 |
Net income tax benefit | $ (36,356) | $ 0 |
Note 15 - Income Taxes - Reconc
Note 15 - Income Taxes - Reconciliation of Effective Tax Rate (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income tax (benefit) expense at statutory rate of 26.5% | $ (5,019,103) | $ 3,776,156 |
Valuation allowance | 5,020,280 | (3,776,156) |
SR&ED credits | (19,198) | 0 |
Other | (18,335) | 0 |
Income tax benefit | (36,356) | 0 |
Growth [Member] | ||
Income tax (benefit) expense at statutory rate of 26.5% | (5,020,280) | 3,776,156 |
Valuation allowance | 5,020,280 | (3,776,156) |
SR&ED credits | 0 | 0 |
Other | 0 | 0 |
Income tax benefit | 0 | 0 |
Digital [Member] | ||
Income tax (benefit) expense at statutory rate of 26.5% | 1,177 | 0 |
Valuation allowance | 0 | 0 |
SR&ED credits | (19,198) | 0 |
Other | (18,335) | 0 |
Income tax benefit | $ (36,356) | $ 0 |
Note 15 - Income Taxes - Reco_2
Note 15 - Income Taxes - Reconciliation of Effective Tax Rate (Details) (Parentheticals) | 12 Months Ended |
Dec. 31, 2020 | |
income tax | 26.50% |
Note 16 - Shareholders' Defic_2
Note 16 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Common Stock, No Par Value (in dollars per share) | $ 0 | $ 0 |
Common Stock, Earned (in shares) | 10,000 | |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,085,343 |
Note 17 - Related Party Trans_2
Note 17 - Related Party Transactions (Details Textual) - USD ($) | 12 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | Dec. 14, 2017 | Dec. 02, 2017 | |
Notes Receivable, Related Parties, Current | $ 0 | $ 17,901 | |||
Accounts Payable, Related Parties, Current | $ 101,422 | 8,347 | |||
CEN Biotech Ukraine [Member] | XN Pharma [Member] | |||||
Ownership Percentage | 49.00% | ||||
CEN Biotech Ukraine [Member] | |||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | ||||
Business Acquisition, Percentage of Voting Interests Acquired | 51.00% | ||||
Emergence Global [Member] | |||||
Notes Receivable, Related Parties, Current | 17,901 | ||||
Joseph Byrne [Member] | |||||
Percentage of Related Party's Equity Interest Owned | 5.00% | ||||
CEN Biotech Ukraine [Member] | |||||
Notes Receivable, Related Parties, Current | 17,901 | ||||
Due from Related Parties, Total | $ 1,299,328 | 1,179,328 | |||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | ||||
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member] | |||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | $ 255,141 | ||||
Notes Receivable, Related Parties | 44,859 | ||||
Board Members and Officers [Member] | Consulting Fees [Member] | |||||
Related Party Transaction, Amounts of Transaction | 188,718 | 124,800 | |||
Due to Related Parties, Total | 518,918 | 330,200 | |||
Chief Technology Officer [Member] | Payoll Expenses [Member] | |||||
Related Party, General and Administrative Expenses | 94,553 | ||||
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member] | |||||
Notes Payable, Related Parties | $ 300,000 | ||||
Director, Joe Byrne [Member] | Advances Made to the Company [Member] | |||||
Accounts Payable, Related Parties, Current | 8,347 | $ 8,347 | |||
The Chief Financial Officer, Alex Tarrabain [Member] | |||||
Accounting Advisory Services, Fees | 13,320 | ||||
The Chief Financial Officer, Alex Tarrabain [Member] | Reimbursable Expenses [Member] | |||||
Accounts Payable, Related Parties, Current | 30,795 | ||||
The Chief Technology Officer, Lawrence Lehoux [Member] | Reimbursable Expenses [Member] | |||||
Accounts Payable, Related Parties, Current | $ 48,960 |
Note 18 - Lease (Including Re_3
Note 18 - Lease (Including Related Parties) (Details Textual) | Aug. 01, 2020USD ($)shares | Oct. 01, 2017CAD ($) | Sep. 30, 2022CAD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021CAD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019 | Jan. 31, 2017 |
Operating Lease, Impairment Loss | $ 0 | $ 146,795 | ||||||
Operating Lease, Liability, Total | $ 310,671 | $ 164,997 | ||||||
Operating Lease, Weighted Average Discount Rate, Percent | 6.76% | 6.76% | ||||||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 4 years 4 months 24 days | 4 years 4 months 24 days | ||||||
Gain (Loss) on Termination of Lease | $ 0 | $ (2,992) | ||||||
General and Administrative Expense [Member] | ||||||||
Operating Lease, Expense | 46,000 | 35,000 | ||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | ||||||||
Operating Lease, Monthly Rent | $ 2,608 | |||||||
Operating Lease, Impairment Loss | $ 146,795 | |||||||
Operating Lease, Liability, Total | 177,686 | 164,997 | ||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | General and Administrative Expense [Member] | ||||||||
Operating Lease, Expense | $ 13,000 | 35,000 | ||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member] | ||||||||
Operating Lease, Monthly Rent | $ 3,390 | |||||||
Lease Arrangement, 20 North Rear Road [Member] | ||||||||
Operating Lease, Weighted Average Discount Rate, Percent | 8.00% | |||||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | |||||||
Operating Lease, Right-of-Use Asset, Write-off | 48,110 | |||||||
Operating Lease, Liability, Write off | 45,118 | |||||||
Gain (Loss) on Termination of Lease | $ 53,692 | |||||||
Lease Arrangement, 20 North Rear Road [Member] | Conversion from Lease Agreement Convertible Debt to Common Stock [Member] | ||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 36,500 | |||||||
Debt Conversion, Converted Instrument, Amount | $ 50,700 | |||||||
Lease Arrangement, 20 North Rear Road [Member] | General and Administrative Expense [Member] | ||||||||
Operating Lease, Expense | $ 20,000 | |||||||
Minimum [Member] | ||||||||
Operating Lease, Monthly Rent | $ 844 | |||||||
Maximum [Member] | ||||||||
Operating Lease, Monthly Rent | $ 5,595 |
Note 18 - Lease (Including Re_4
Note 18 - Lease (Including Related Parties) - Future Minimum Operating Lease Payments (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
2022 | $ 119,543 | |
2023 | 90,325 | |
2024 | 61,897 | |
2025 | 32,088 | |
2026 | 32,088 | |
Thereafter | 24,066 | |
Total lease payments | 360,007 | |
Less imputed interest | 49,336 | |
Present value of lease liability | $ 310,671 | $ 164,997 |
Note 19 - Stock Based Compens_3
Note 19 - Stock Based Compensation (Details Textual) - USD ($) | Dec. 06, 2021 | Jul. 13, 2021 | Jun. 25, 2021 | Apr. 02, 2021 | Aug. 27, 2020 | Apr. 17, 2020 | Apr. 02, 2020 | May 16, 2019 | Nov. 30, 2017 | Jun. 25, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 29, 2017 |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,085,343 | ||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 500,000 | 162,500 | 225,000 | ||||||||||
Stock Issued During Period, Value, Issued for Services | $ 162,000 | $ 1,172,000 | $ 279,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | 16,562,822 | $ 1,237,250 | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 738,250 | ||||||||||||
President [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 8,750,000 | ||||||||||||
President [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 7,400,000 | ||||||||||||
Chief Executive Officer [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||
Accrued Salaries | $ 58,500 | ||||||||||||
Number of Restricted Shares to settle Accrued Salaries (in shares) | 337,500 | ||||||||||||
Chief Executive Officer [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 325,000 | ||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,500,000 | ||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,140,000 | ||||||||||||
Vice President [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 750,000 | ||||||||||||
Vice President [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 300,000 | ||||||||||||
Chief Financial Officer [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||
Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 350,000 | ||||||||||||
Senior Vice President of Deals and Acquisitions [Member] | |||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 2,500,000 | ||||||||||||
Senior Vice President of Deals and Acquisitions [Member] | Vested Immediately [Member] | |||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 700,000 | ||||||||||||
Director, Harold Aubrey de Lavenu [Member] | |||||||||||||
Annual Salary | $ 31,200 | ||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,870,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,330,000 | ||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 550,000 | ||||||||||||
Restricted Stock [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 15,059,291 | 387,500 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 13,559,291 | 1,987,500 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $ 275,000 | $ 117,000 | $ 16,871,822 | $ 279,000 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value | $ 29,885,063 | $ 13,013,241 | |||||||||||
Restricted Stock [Member] | CONFIEN SAS [Member] | |||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 650,000 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 897,000 | ||||||||||||
Restricted Stock [Member] | Senior Vice President of Deals and Acquisitions [Member] | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 238,000 | ||||||||||||
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,041,250 | ||||||||||||
Restricted Stock [Member] | Director, Ameen Ferris [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||
Restricted Stock [Member] | Directors Ameen Ferris and Harold Aubrey De Lavenu [Member] | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 2,816,925 | ||||||||||||
Restricted Stock [Member] | Richard Boswell [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 2,185,679 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 3,016,237 | ||||||||||||
Restricted Stock [Member] | Bahige Chaaban [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,106,122 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 4,286,435 | ||||||||||||
Restricted Stock [Member] | Brian Payne [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,435,000 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,980,300 | ||||||||||||
Restricted Stock [Member] | Usamakh Saadikh [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,380,000 | ||||||||||||
Restricted Stock [Member] | Donald Strilchuck [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 341,250 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 470,925 | ||||||||||||
Restricted Stock [Member] | Director, Alex Tarrabain [Member] | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | 300,000 | |||||||||||
Stock Issued During Period, Value, Issued for Services | $ 899,000 | ||||||||||||
2017 Equity Compensation Plan [Member] | |||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 | ||||||||||||
The 2021 Equity Compensation Plan [Member] | |||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 |
Note 19 - Stock Based Compens_4
Note 19 - Stock Based Compensation - Compensation Expenses (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Stock Based Compensation [Member] | ||
Compensation expense | $ 15,390,822 | $ 746,300 |
Professional Fees [Member] | ||
Compensation expense | 1,172,000 | 279,000 |
Stock Based Compensation and Professional Fees [Member] | ||
Compensation expense | $ 16,562,822 | $ 1,025,300 |
Note 19 - Stock Based Compens_5
Note 19 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Non-vested, number of share (in shares) | 2,025,000 | 425,000 | 2,025,000 | |
Non-vested, weighted average grant date fair value (in dollars per share) | $ 0.76 | $ 1.01 | $ 0.76 | |
Non-vested, weighted average remaining contractual term (Year) | 2 years 10 months 2 days | 1 year 6 months | 1 year 6 months 14 days | |
Granted, number of share (in shares) | 15,059,291 | 387,500 | ||
Granted, weighted average grant date fair value (in dollars per share) | $ 1.12 | $ 0.72 | ||
Vested, number of share (in shares) | (13,559,291) | (1,987,500) | ||
Vested, weighted average grant date fair value (in dollars per share) | $ 1.22 | $ 0.70 | ||
Forfeited, number of share (in shares) | 0 | 0 | ||
Forfeited, weighted average grant date fair value (in dollars per share) | $ 0 | $ 0 | ||
Non-vested, number of share (in shares) | 1,925,000 | 425,000 | 2,025,000 | |
Non-vested, weighted average grant date fair value (in dollars per share) | $ 0.38 | $ 1.01 | $ 0.76 |
Note 20 - Other Receivable (Det
Note 20 - Other Receivable (Details Textual) - Line of Credit to Clear Com [Member] | Dec. 31, 2020USD ($) | May 31, 2017USD ($) | May 31, 2017CAD ($) |
Unfunded Line of Credit Commitment, Maximum | $ 785,400 | $ 1,000,000 | |
Receivables, Interest Rate | 2.00% | 2.00% | |
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 0 |
Note 21 - Net (Loss) Income P_3
Note 21 - Net (Loss) Income Per Share - Antidilutive Securities (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Convertible Debt Securities [Member] | ||
Antidilutive Securities (in shares) | 1,085,343 | 0 |
Tesla Agreement Securities [Member] | ||
Antidilutive Securities (in shares) | 0 | 1,000,000 |
Note 21 - Net Income (Loss) Per
Note 21 - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income available to common stockholders | $ 14,249,645 | |
Shares, Basic (in shares) | 42,417,416 | 27,264,072 |
Per share, Basic (in dollars per share) | $ (0.45) | $ 0.52 |
Effect of Dilutive Securities, Convertible debt | $ 585,392 | |
Shares, Convertible debt (in shares) | 5,468,438 | |
Income available to common stockholders with assumed conversions | $ 14,835,037 | |
Shares, Diluted (in shares) | 42,417,416 | 32,732,510 |
Per share, Diluted (in dollars per share) | $ (0.45) | $ 0.45 |
Note 22 - Fair Value Disclosu_3
Note 22 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 193,198 | $ 1,908 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 527,379 |
Loans payable – related parties | 2,701,641 | 1,363,354 |
Convertible notes payable | 643,330 | 6,730,448 |
Convertible notes payable – related parties | 162,639 | 2,558,681 |
Other receivables | 113,999 | |
Patent acquisition liability | 1,380,000 | |
Reported Value Measurement [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 31,552 | |
Reported Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,179,328 |
Reported Value Measurement [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 17,901 | |
Estimate of Fair Value Measurement [Member] | ||
Cash and cash equivalents | 193,198 | 1,908 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 527,379 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 1,890,736 | 7,766,663 |
Convertible notes payable – related parties | 0 | 0 |
Other receivables | 113,999 | |
Patent acquisition liability | 1,380,000 | |
Estimate of Fair Value Measurement [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 31,552 | |
Estimate of Fair Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,179,328 |
Estimate of Fair Value Measurement [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 17,901 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Other receivables | 0 | |
Patent acquisition liability | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 193,198 | 1,908 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Other receivables | 0 | |
Patent acquisition liability | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 527,379 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 1,890,736 | 7,766,663 |
Convertible notes payable – related parties | 0 | 0 |
Other receivables | 113,999 | |
Patent acquisition liability | 1,380,000 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 31,552 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | $ 1,299,328 | 1,179,328 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | $ 17,901 |
Note 23 - Segment Information -
Note 23 - Segment Information - Segment Information (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | $ 626,867 | $ 0 |
Operating (loss) income | (19,037,541) | (2,543,730) |
Depreciation expense | 22,164 | 10,724 |
Interest income | 504 | 6,400 |
Interest expense | 428,249 | 3,233,421 |
Income tax benefit | 36,356 | 0 |
Capital expenditures | 23,213 | 0 |
Growth [Member] | ||
Revenue | 0 | 0 |
Operating (loss) income | (19,042,415) | (2,543,730) |
Depreciation expense | 0 | 10,724 |
Amortization expense | 424,812 | 424,812 |
Interest income | 394 | 6,400 |
Interest expense | 846,749 | 3,676,858 |
Income tax benefit | 0 | 0 |
Capital expenditures | 0 | 0 |
Digital [Member] | ||
Revenue | 626,867 | 0 |
Operating (loss) income | 4,874 | 0 |
Depreciation expense | 22,164 | 0 |
Amortization expense | 14,731 | 0 |
Interest income | 110 | 0 |
Interest expense | 0 | 0 |
Income tax benefit | 36,356 | 0 |
Capital expenditures | $ 23,213 | $ 0 |
Note 23 - Segment Information_2
Note 23 - Segment Information - Segment Assets to Total Assets (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Total assets | $ 8,440,799 | $ 6,314,142 |
Growth [Member] | ||
Total assets | 5,900,371 | 6,314,142 |
Digital [Member] | ||
Total assets | $ 2,540,428 | $ 0 |
Note 25 - Subsequent Events (De
Note 25 - Subsequent Events (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Feb. 28, 2022USD ($) | Mar. 31, 2022USD ($) | Dec. 31, 2021 | |
Convertible Debt [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 914,732 | ||
Subsequent Event [Member] | |||
Advances to Affiliate | $ 1,299,328 | ||
Accounts Receivable, Allowance for Credit Loss, Writeoff | $ 44,859 | ||
Subsequent Event [Member] | Convertible Debt [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 416,667 | ||
Debt Instrument, Face Amount | $ 100,000 |